The GibsonGroup report the use of their (patent pending) macromolecular cryoprotectants for the cryopreservation of stem (stromal) cells. With this technology the amount of DMSO was reduced required for cryopreservation was reduced from 10 wt % to just 2.5 wt %. These findings are important for regenerative medicine applications where high-quality frozen cells are crucial, and the reduced DMSO may reduce toxicity and improve stem cell manufacturing processes. 
https://doi.org/10.1021/acsabm.0c00638